Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.92 |
| ▸ | BCHE | P06276 | 9/20 | 0.92 |
| ▸ | EP300 | Q09472 | 5/20 | 0.92 |
| ▸ | LMNA | P02545 | 3/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.92 |
| ▸ | MAPT | P10636 | 3/20 | 0.92 |
| ▸ | RAD52 | P43351 | 3/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.92 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.92 |
| ▸ | DRD2 | P14416 | 2/20 | 0.92 |
| ▸ | TSHR | P16473 | 2/20 | 0.92 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.92 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.92 |
| ▸ | RXRA | P19793 | 2/20 | 0.92 |
| ▸ | DRD1 | P21728 | 2/20 | 0.92 |
| ▸ | HTR2B | P41595 | 2/20 | 0.92 |
| ▸ | HTT | P42858 | 2/20 | 0.92 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Berberine SCHEMBL29354144 | 0.96 | ACHE (1.00) | ACHEBCHEEP300LMNACYP3A4 | |
| Berberine SCHEMBL15669190 | 0.96 | ACHE (1.00) | ACHEBCHEEP300LMNACYP3A4 | |
| Berberine SCHEMBL25632 | 0.96 | ACHE (1.00) | ACHEBCHEEP300LMNACYP3A4 | |
| Berberine SCHEMBL30153843 | 0.96 | ACHE (1.00) | ACHEBCHEEP300LMNACYP3A4 | |
| Berberine SCHEMBL4894622 | 0.95 | BCHE (0.98) | ACHEBCHEEP300LMNACYP3A4 | |
| Berberine SCHEMBL1376273 | 0.95 | ACHE (0.98) | ACHEBCHEEP300LMNACYP3A4 | |
| Berberine SCHEMBL3686644 | 0.95 | ACHE (0.98) | ACHEBCHEEP300LMNACYP3A4 | |
| Berberine SCHEMBL21462194 | 0.95 | ACHE (0.98) | ACHEBCHEEP300LMNACYP3A4 | |
| Berberine SCHEMBL153906 | 0.95 | ACHE (1.00) | ACHEBCHEEP300LMNACYP3A4 | |
| Berberine SCHEMBL2538316 | 0.95 | ACHE (0.98) | ACHEBCHEEP300LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361625-A1 | Methods and compositions for the treatment of hyperlipidemia | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2011-08-31 | — | — | EP | claimed |
| US-20110158932-A1 | Methods And Compositions For The Treatment of Hyperlipidemia | ABBOTT LABORATORIES | 2011-06-30 | — | — | US | claimed |
| EP-1796666-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERLIPIDEMIA | INST MEDICINAL BIOTECHNOLOGY (CN) | 2008-03-19 | — | — | EP | claimed |
| CN-101102768-A | Method and composition for the treatment of hyperlipidemia | MEDICINE AND BIOENGINEERING IN (CN) | 2008-01-09 | — | — | CN | claimed |
| EP-1796666-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERLIPIDEMIA | Institute of Medicinal Biotechnology, Chinese Acadamy of Medical Sciences (CN) | 2007-06-20 | — | — | EP | claimed |
| US-20060223838-A1 | Methods and compositions for the treatment of hyperlipidemia | INSTITUTE OF MEDICINAL BIOTECHNOLOGY (CN) | 2006-10-05 | — | — | US | claimed |
| WO-2006029577-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERLIPIDEMIA | INST MEDICINAL BIOTECHNOLOGY (CN) | 2006-05-26 | — | — | WO | claimed |
| WO-2006029577-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERLIPIDEMIA | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2006-03-23 | — | — | WO | claimed |
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
| WO-2021067490-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2021-04-08 | — | — | WO | disclosed |
| CN-105777632-A | Aromatic-ring azacyclo derivatives and application thereof | 成都贝斯凯瑞生物科技有限公司 | 2016-07-20 | — | — | CN | disclosed |
| CN-105777633-A | Tetrahydroisoquinoline derivative and application thereof | 成都贝斯凯瑞生物科技有限公司 | 2016-07-20 | — | — | CN | disclosed |
| CN-105753817-A | Nitrogen-substituted heterocyclic derivatives and application thereof | 成都贝斯凯瑞生物科技有限公司 | 2016-07-13 | — | — | CN | disclosed |
| CN-105753814-A | Substituted nitrogen heterocyclic derivative and application thereof | 成都贝斯凯瑞生物科技有限公司 | 2016-07-13 | — | — | CN | disclosed |
| EP-1796666-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERLIPIDEMIA | INST MEDICINAL BIOTECHNOLOGY (CN) | 2008-03-19 | — | — | EP | disclosed |
| CN-101102768-A | Method and composition for the treatment of hyperlipidemia | MEDICINE AND BIOENGINEERING IN (CN) | 2008-01-09 | — | — | CN | disclosed |
| EP-1796666-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERLIPIDEMIA | Institute of Medicinal Biotechnology, Chinese Acadamy of Medical Sciences (CN) | 2007-06-20 | — | — | EP | disclosed |
| US-20060223838-A1 | Methods and compositions for the treatment of hyperlipidemia | INSTITUTE OF MEDICINAL BIOTECHNOLOGY (CN) | 2006-10-05 | — | — | US | disclosed |
| WO-2006029577-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERLIPIDEMIA | INST MEDICINAL BIOTECHNOLOGY (CN) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006029577-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERLIPIDEMIA | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | LIPC, FABP1, CPT1A | ACHE 2228/4885BCHE 795/4885EP300 212/4885 |
| US-20110158932-A1 | Methods And Compositions For The Treatment of Hyperlipidemia | PCSK9, APOB, LDLR | ACHE 69/4885BCHE 33/4885EP300 3709/4885 |
| US-20060223838-A1 | Methods and compositions for the treatment of hyperlipidemia | PCSK9, APOB, LDLR | ACHE 69/4885BCHE 33/4885EP300 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.